AmBisome must be diluted with 5% Dextrose Injection to a final concentration of 1 to 2 mg/mL prior to administration. Lower concentrations (0.2 to 0.5 mg/mL) may be appropriate for infants …
FDA Label for Ambisome - NDC List
Dec 5, 2025 · Product labels may durg indications and usage, generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, warnings, inactive …
AmBisome (Astellas Pharma US, Inc.): FDA Package Insert
Jun 11, 2025 · Am B isome ® for Injection is a sterile, non-pyrogenic lyophilized product for intravenous infusion.
AmBisome® | AmBisome (amphotericin B) liposome for injection
Am B isome is indicated for the following: Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with Am B isome, relapse …
AMBISOME- amphotericin b injection, powder, lyophilized, for …
Am B isome for Injection is a sterile, non-pyrogenic lyophilized product for intravenous infusion.
Administration: intravenous infusion over a 30 – 60 min period, or over a 2 hour period for doses greater than 5mg/kg/day.
PRESCRIBING INFORMATION AMBISOME® liposomal amphotericin B 50 mg powder for solution for infusion. d children aged 1 month - 18 years: 1) Severe systemic and/or deep …
AmBisome - FDA Drug Approval Details - trial.medpath.com
Detailed FDA approval information for AmBisome, including regulatory status, product details, and official drug labeling information.
AmBisome (amphotericin B liposomal) dosing, indications, …
Indicated for empiric therapy for presumed fungal infection in febrile, neutropenic patients. 3 mg/kg IV qDay.
DailyMed
Sep 15, 2021 · The DailyMed database contains 155332 labeling submitted to the Food and Drug Administration (FDA) by companies. DailyMed does not contain a complete listing of labeling …